mehmetaltanmd (@mehmetaltanmd) 's Twitter Profile
mehmetaltanmd

@mehmetaltanmd

Thoracic/Head and Neck Medical Oncology

ID: 1169969562261118976

calendar_today06-09-2019 13:44:25

1 Tweet

63 Followers

17 Following

ACS Journal Cancer (@journalcancer) 's Twitter Profile Photo
ACS Journal Cancer
@journalcancer

a year ago

Presented at #IASLC22 | Investigator-initiated trial selinexor & pembrolizumab demonstrated antitumor activity in patient subsets with metastatic NSCLC, with no new safety signals. 🔗 acsjournals.onlinelibrary.wiley.com/doi/full/10.10… mehmetaltanmd MD Anderson Cancer Center CC: @Ramalingam, OncoAlert, IASLC

Presented at #IASLC22 | Investigator-initiated trial selinexor &amp; pembrolizumab demonstrated antitumor activity in patient subsets with metastatic NSCLC, with no new safety signals. 🔗 acsjournals.onlinelibrary.wiley.com/doi/full/10.10… <a href="/MehmetAltanMD/">mehmetaltanmd</a> <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> CC: @Ramalingam, <a href="/OncoAlert/">OncoAlert</a>, <a href="/IASLC/">IASLC</a>